Abstract
Remoxipride is a novel substituted benzamide derivative with specific dopamine-(D2)-receptor blocking properties and selective action on brain mesolimbic functions. Ten inpatients with a DSM-III diagnosis of schizophrenia were treated with the drug in a 6-week open-label study. After 1 week placebo washout, the patients were given stepwise increased doses from 20 to 100 mg t.i.d. Most patients showed a clinically significant improvement; the mean scores in the Brief Psychiatric Rating Scale decreased from 25.8 at baseline to 11.3 at endpoint. Few adverse events were recorded and the rated extrapyramidal symptoms were lower at endpoint than at baseline. No abnormalities in clinical chemistry, haematology, cardiovascular assessments or EEG recordings were seen.
References
American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, third ed. (DSM-III). Washington, D.C., A.P.A.
Florvall L, Ögren S-O (1982) Potential neuroleptic agents. 2,6-dialkoxybenzamide derivatives with potent dopamine receptor blocking activities. J Med Chem 25:1280–1286
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96
Ögren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Ängeby K, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102:459–474
Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812
Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 45, Suppl. 212:11–19
Widerlöv (1984) Remoxipride — a potential antipsychotic drug with selective dopamine D2 receptor properties. Clin Neuropharmacol, 7, Suppl. 1:554–555
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lindström, L., Besev, G., Stening, G. et al. An open study of remoxipride, a benzamide derivative, in schizophrenia. Psychopharmacology 86, 241–243 (1985). https://doi.org/10.1007/BF00431718
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00431718